1 results found.

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Clinical Trial using ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years to 69 years.
- Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma.
ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis